Trevi Therapeutics, Inc.TRVINASDAQ
Loading
SG&A Expense Growth Recovery in ProgressRecovering
Percentile Rank44
5Y CAGR-13.7%
Year-over-Year Change
Year-over-year SG&A expense growth
5Y CAGR
-13.7%/yr
Long-term compound
Percentile
P44
Within normal range
vs 5Y Ago
0.5x
Contraction
Streak
1 qtr
Consecutive growthRecovering
| Period | Value |
|---|---|
| Q4 2025 | 4.31% |
| Q3 2025 | -11.59% |
| Q2 2025 | 18.42% |
| Q1 2025 | 27.18% |
| Q4 2024 | 0.49% |
| Q3 2024 | -11.36% |
| Q2 2024 | 5.31% |
| Q1 2024 | 28.87% |
| Q4 2023 | -12.56% |
| Q3 2023 | 7.17% |
| Q2 2023 | -0.90% |
| Q1 2023 | 9.53% |
| Q4 2022 | -11.23% |
| Q3 2022 | -2.98% |
| Q2 2022 | 14.16% |
| Q1 2022 | 13.66% |
| Q4 2021 | -6.06% |
| Q3 2021 | -16.49% |
| Q2 2021 | 6.76% |
| Q1 2021 | -5.05% |
| Q4 2020 | 8.98% |
| Q3 2020 | -3.05% |
| Q2 2020 | -4.89% |
| Q1 2020 | 34.84% |
| Q4 2019 | -2.85% |
| Q3 2019 | 5.88% |
| Q2 2019 | 28.15% |
| Q1 2019 | 4.84% |
| Q4 2018 | 16.20% |
| Q3 2018 | 28.59% |
| Q2 2018 | 20.80% |
| Q1 2018 | 24.84% |
| Q4 2017 | 0.00% |